SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: technetium who wrote (20723)8/1/2006 2:52:44 PM
From: technetium  Read Replies (1) | Respond to of 52153
 
Plus even after approval for Crohn's (if that ever happens - probably a tough sell as far as the FDA is concerned), ELN and BIIB split the profits from Tysabri, so it's hard to believe will earn anything like $8/share from it.



To: technetium who wrote (20723)8/1/2006 5:49:46 PM
From: Robohogs  Read Replies (1) | Respond to of 52153
 
That was the point of my post. I questioned the numbers over there - never heard back.

Jon

PS I expect T sales by the may be closer to $1 B, depending on new therapies coming.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News